Opexa Therapeutics Inc. (NASDAQ:OPXA) received a $18.00 price objective from Maxim Group in a report issued on Tuesday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price indicates a potential upside of 462.50% from the stock’s previous close.

Several other research firms also recently weighed in on OPXA. Aegis raised their target price on shares of Opexa Therapeutics to $11.00 and gave the company a “buy” rating in a report on Monday, July 18th. Zacks Investment Research downgraded shares of Opexa Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 9th. Finally, Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Opexa Therapeutics in a report on Sunday, July 3rd.

Opexa Therapeutics (NASDAQ:OPXA) opened at 3.20 on Tuesday. The stock has a 50 day moving average of $4.10 and a 200 day moving average of $3.28. Opexa Therapeutics has a one year low of $1.69 and a one year high of $5.10. The firm’s market capitalization is $22.56 million.

Opexa Therapeutics (NASDAQ:OPXA) last announced its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. Opexa Therapeutics had a negative net margin of 324.97% and a negative return on equity of 109.48%. During the same quarter last year, the firm posted ($0.56) earnings per share. Analysts forecast that Opexa Therapeutics will post ($1.12) earnings per share for the current year.

An institutional investor recently raised its position in Opexa Therapeutics stock. Renaissance Technologies LLC boosted its position in Opexa Therapeutics Inc. (NASDAQ:OPXA) by 9.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,189 shares of the biopharmaceutical company’s stock after buying an additional 12,900 shares during the period. Renaissance Technologies LLC owned about 2.16% of Opexa Therapeutics worth $344,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.40% of the company’s stock.

Opexa Therapeutics Company Profile

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

5 Day Chart for NASDAQ:OPXA

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.